About this Journal Submit a Manuscript Table of Contents
Bone Marrow Research
Volume 2012 (2012), Article ID 375075, 8 pages
http://dx.doi.org/10.1155/2012/375075
Clinical Study

CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients

1Department of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Rudolfa Weigla Street, 53-114 Wroclaw, Poland
2Lower Silesian Center for Cellular Transplantation, National Bone Marrow Donor Registry, Grabiszyńska 105, 53-439 Wroclaw, Poland

Received 28 July 2012; Revised 24 September 2012; Accepted 24 September 2012

Academic Editor: Bronwen Shaw

Copyright © 2012 Emilia Jaskula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Ljungman, “Risk assessment in haematopoietic stem cell transplantation: viral status,” Best Practice and Research, vol. 20, no. 2, pp. 209–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. International Standards for Cellular Therapy Product Collection, Processing, and Administration, chapter 6, FACT-JACIE Standards, 4th edition, 2008.
  3. J. W. Gratama, J. W. J. Van Esser, C. H. J. Lamers et al., “Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection,” Blood, vol. 98, no. 5, pp. 1358–1364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. H. T. Maeker and V. C. Maino, “Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry,” Human Immunology, vol. 65, no. 5, pp. 493–499, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Sester, B. C. Gärtner, U. Sester, M. Girndt, N. Mueller-Lantzsch, and H. Köhler, “Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity,” Transplantation, vol. 76, no. 8, pp. 1229–1230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Roback, “CMV and blood transfusions,” Reviews in Medical Virology, vol. 12, no. 4, pp. 211–219, 2002. View at Publisher · View at Google Scholar
  7. M. Boeckh and W. G. Nichols, “The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy,” Blood, vol. 103, no. 6, pp. 2003–2008, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. W. G. Nichols, L. Corey, T. Gooley, C. Davis, and M. Boeckh, “High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection,” Journal of Infectious Diseases, vol. 185, no. 3, pp. 273–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. B. McGlave, X. O. Shu, W. Wen et al., “Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program,” Blood, vol. 95, no. 7, pp. 2219–2225, 2000. View at Scopus
  10. P. Ljungman, K. Larsson, G. Kumlien et al., “Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors,” Scandinavian Journal of Infectious Diseases, vol. 34, no. 5, pp. 347–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ljungman, R. Brand, H. Einsele, F. Frassoni, D. Niederwieser, and C. Cordonnier, “Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis,” Blood, vol. 102, no. 13, pp. 4255–4260, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Jaskula, D. Dlubek, D. Duda, K. Bogunia-Kubik, A. Mlynarczewska, and A. Lange, “Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4+ lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients,” Biology of Blood and Marrow Transplantation, vol. 15, no. 10, pp. 1296–1305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Jaskula, D. Dlubek, M. Sedzimirska, D. Duda, A. Tarnowska, and A. Lange, “Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation,” Transplantation Proceedings, vol. 42, no. 8, pp. 3273–3276, 2010. View at Publisher · View at Google Scholar · View at Scopus